Evidence map›Paper›PMID 41296747›Full record

ArticleGenetics2026

Preventing evolutionary rescue in cancer using two-strike therapy.

Srishti Patil, Armaan Ahmed, Yannick Viossat, Robert Noble

Abstract read
In one paragraph

Article in Genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Srishti PatilDepartment of Mathematics, City St George's, University of London, London EC1V 0HB, United Kingdom.
Armaan AhmedDepartment of Applied Mathematics & Statistics, Johns Hopkins University, Baltimore, MD 21218, United States.
Yannick ViossatCEREMADE, Université Paris-Dauphine, Université PSL, CNRS, Paris 75016, France.
Robert NobleDepartment of Mathematics, City St George's, University of London, London EC1V 0HB, United Kingdom.ORCID 0000-0002-8057-4252

Funding

The Role of the Microbiome in Cancer Suppression and Susceptibility Across SpeciesU54CA217376 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI MALEY, CARLO · 2018 to 2022
$8.6M
Horizon 2020London Mathematical Society Research in Pairs 42320Marie Skłodowska-Curie 955708National Cancer Institute of the National Institutes of Health U54CA217376NCI NIH HHS U54 CA217376
6 · The paper itself

Abstract

First-line cancer treatment frequently fails due to initially rare therapeutic resistance. An important clinical question is then how to schedule subsequent treatments to maximize the probability of tumor eradication. Here, we provide a theoretical solution to this problem by using mathematical analysis and extensive stochastic simulations within the framework of evolutionary rescue theory to determine how best to exploit the vulnerability of small tumors to stochastic extinction. Whereas standard clinical practice is to wait for evidence of relapse, we confirm a recent hypothesis that the optimal time to switch to a second treatment is when the tumor is close to its minimum size before relapse, when it is likely undetectable. This optimum can lie slightly before or slightly after the nadir, depending on tumor parameters. Given that this exact time point may be difficult to determine in practice, we study windows of high extinction probability that lie around the optimal switching point, showing that switching after the relapse has begun is typically better than switching too early. We further reveal how treatment efficacy and tumor demographic and evolutionary parameters influence the predicted clinical outcome, and we determine how best to schedule drugs of unequal efficacy. Our work establishes a foundation for further experimental and clinical investigation of this evolutionarily-informed multi-strike treatment strategy.

Indexed as

NeoplasmsBiological EvolutionDrug Resistance, NeoplasmHumanscancer treatmentevolutionary rescueevolutionary therapyextinction therapymathematical oncologytherapeutic resistance

Identifiers

PMID41296747
PMCPMC13270307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.